Mumps-Measles-Rubella vaccine (MMR)

Generic name
Mumps-Measles-Rubella vaccine (MMR)
Brand name
ATC Code
J07BD52
Compare …

Mumps-Measles-Rubella vaccine (MMR)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Measles-mumps-rubella (MMR) vaccination
  • Subcutaneous
    • 14 months
      [1]
      • NATIONAL VACCINATION PROGRAMME: First vaccination 0.5 ml/dose, once only.
    • 9 years
      [1]
      • NATIONAL VACCINATION PROGRAMME 2nd vaccination 0.5 ml/dose, once only.
    • 9 months up to 12 months
      [1] [2] [3] [4]
      • 0.5 ml/dose, once only.

      • In certain cases it may be desirable to give the BMR vaccination earlier, for example in outbreak situations, day care or a trip to a region where measles is frequent. The National Vaccination Program indicates that this can be done from 6 months of age. Children who are vaccinated before the age of 12 months should be vaccinated again at the age of 12-15 months.

  • Intramuscular
    • 14 months
      [1]

      • NATIONAL VACCINATION PROGRAMME: first vaccination 0.5 ml/dose once only

    • 9 years
      [1]

      • NATIONAL VACCINATION PROGRAMME: second vaccination 0.5 ml/dose once only

    • 9 months up to 12 months
      [1] [2] [3] [4]
      • 0.5 ml/dose, once only.

      • In certain cases it may be desirable to give the BMR vaccination earlier, for example in outbreak situations, day care or a trip to a region where measles is frequent. The National Vaccination Program indicates that this can be done from 6 months of age. Children who are vaccinated before the age of 12 months should be vaccinated again at the age of 12-15 months.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Children aged 9–12 months sometimes have an inadequate response to the vaccine due to circulating maternal antibodies and / or insufficient development of the immune system. However, it may be necessary to vaccinate, eg in outbreak situations, day care or when traveling to a region where measles is common.

If the vaccine is to be given simultaneously with another injectable vaccine, always administer the vaccines at different injection sites. In other cases, maintain an interval of at least four weeks.

Live vaccines (such as the BMR vaccine) should not be administered to infants exposed to infliximab in utero until 12 months after birth. Administration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not recommended unless serum levels of infliximab are undetectable in the infant. These infants may be at increased risk for infection, including severe disseminated infection that may become fatal. [DHPC]

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

VIRAL VACCINES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Encephalitis vaccines
J07BA02
J07BA01
Influenza vaccines
J07BB02
Hepatitis vaccines
J07BC20
J07BC02
J07BC01
Poliomyelitis vaccines
J07BF03
Rabies vaccines
J07BG01
Rota virus diarrhea vaccines
J07BH01
Varicella zoster vaccines
J07BK01
Yellow fever vaccines
J07BL01
Papillomavirus vaccines
J07BM03
J07BM02
Other viral vaccines
J07BX04

References

  1. RijksInstituut voor Volksgezondheid en Milieu (RIVM), Rijksvaccinatieprogramma: vaccinatieschema versie 1.0 , https://rijksvaccinatieprogramma.nl/documenten/rvp-richtlijn-uitvoering-rvp-2020, 18 dec 2020
  2. MSD VACCINS, SmPC MMRVaxpro (EU/1/06/337) Rev 26, 04-12-2020, www.emea.europa.eu
  3. GlaxoSmithKline BV, SPC Priorix, RVG 22052 (geraadpleegd 23 okt 2009), www.cbg-meb.nl, http://db.cbg-meb.nl/IB-teksten/h22052.pdf
  4. GlaxoSmithKline BV, SPC Priorix, RVG 22052 (geraadpleegd 23 okt 2009), www.cbg-meb.nl, http://db.cbg-meb.nl/IB-teksten/h22052.pdf
  5. Representatives of marketing authorisation holders of infliximab, DHPC Infliximab 07 maart 2022,, https://www.cbg-meb.nl/documenten/brieven/2022/03/08/dhpc-infliximab

Changes

Therapeutic Drug Monitoring


Overdose